A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
Westphal, Manfred, Heese, Oliver, Steinbach, Joachim P., Schnell, Oliver, Schackert, Gabriele, Mehdorn, Maximilian, Schulz, Dirk, Simon, Matthias, Schlegel, Uwe, Senft, Christian, Geletneky, Karsten,Том:
51
Мова:
english
Журнал:
European Journal of Cancer
DOI:
10.1016/j.ejca.2014.12.019
Date:
March, 2015
Файл:
PDF, 1.20 MB
english, 2015
File converter
Більше результатів пошуку
More benefits 
